The CHI-S model provides a path for fast, proof-of-concept human trialling of schistosomiasis vaccines, and would be suitable for assessing the effectiveness of the currently available Sm14 and Sm-TSP-2 antigens; other vaccine candidates [65], either separately or in combination, could similarly be evaluated. The gene discussed is THBS2; the disease is schistosomiasis.